Tscan Therapeutics Inc Asset Turnover Ratio (TCRX), as of second quarter 2026, current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Tscan Therapeutics Inc   (NASDAQ: TCRX)
 

Tscan Therapeutics Inc Asset Turnover Ratio

Quarterly Results, Trends, Rankings, Statistics

Tscan Therapeutics Inc 's asset turnover ratio, the ratio that measures the ability of Tscan Therapeutics Inc 's assets to generate revenue, sequentially decreased to 0.03 in the second quarter (Jun 30 2026), which does not come as a surprise, as the Tscan Therapeutics Inc continue to experience difficult business climate.

Within sector 64 more businesses have achieved higher asset turnover ratio. While Asset turnover ratio total ranking has improved so far during the II Quarter 2026, to 3576, from total ranking in the first quarter 2026 at 4130.

Asset Turnover Ratio Definition


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TCRX Asset Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Asset Change -42.57 % -39.29 % -24.17 % -7.46 % -3.34 %
Y / Y Revenue Change -65.83 % -54.77 % 286.02 % 139.37 % 473.88 %
Asset Turnover Ratio (TTM) 0.03 0.04 0.04 0.03 0.02
TCRX's Total Ranking # 3576 # 4130 # 3864 # 3990 # 4075
Seq. Asset Change -15.12 % -11.71 % -12.75 % -12.17 % -10.26 %
Seq. Revenue Change 7.03 % -61.75 % 2.23 % -18.37 % 41.69 %



Asset Turnover Ratio Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 65
Healthcare Sector # 525
Overall Market # 3576

Asset Turnover Ratio Statistics
High Average Low
0.1 0.04 0.01
(Mar 31 2023)   (Dec 31 2024)




TCRX Company Profile • Back to TCRX Efficiency Comparisons • Compare TCRX Asset Turnover Ratio to its Competitors



Companies with similar Asset Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Asset Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Assets at quarter ending Jun 30 2026
Tonix Pharmaceuticals Holding Corp   0.11 $ 29.102  Millions$ 260.403  Millions
Beam Therapeutics Inc   0.11 $ 156.035  Millions$ 1,414.853  Millions
Surrozen Inc   0.11 $ 11.511  Millions$ 107.272  Millions
C4 Therapeutics Inc   0.11 $ 35.039  Millions$ 328.207  Millions
Scilex Holding Company  0.11 $ 31.608  Millions$ 297.014  Millions
Ginkgo Bioworks Holdings Inc   0.10 $ 111.863  Millions$ 1,082.996  Millions
Zymeworks Inc   0.09 $ 37.127  Millions$ 404.744  Millions
Nektar Therapeutics  0.09 $ 54.589  Millions$ 610.038  Millions
Bolt Biotherapeutics Inc   0.09 $ 4.700  Millions$ 52.543  Millions
Therapeuticsmd Inc   0.09 $ 3.270  Millions$ 37.859  Millions
Lenz Therapeutics Inc   0.08 $ 21.475  Millions$ 256.428  Millions
Lipocine Inc   0.08 $ 1.569  Millions$ 20.568  Millions
Longeveron Inc   0.08 $ 1.187  Millions$ 15.629  Millions
Armata Pharmaceuticals Inc   0.07 $ 6.034  Millions$ 81.537  Millions
Intellia Therapeutics Inc   0.07 $ 59.506  Millions$ 845.836  Millions
Cytomx Therapeutics Inc   0.07 $ 18.302  Millions$ 262.601  Millions
Catheter Precision Inc   0.07 $ 1.915  Millions$ 28.322  Millions
Metagenomi Therapeutics Inc   0.06 $ 13.561  Millions$ 209.924  Millions
Nurix Therapeutics Inc   0.06 $ 36.766  Millions$ 595.569  Millions
EBR Systems, Inc.  0.06 $ 6.446  Millions$ 105.295  Millions
Caribou Biosciences Inc   0.06 $ 10.035  Millions$ 165.531  Millions
Grail Inc   0.06 $ 165.263  Millions$ 2,792.551  Millions
Ispecimen inc   0.06 $ 0.466  Millions$ 8.133  Millions
Nexalin Technology Inc   0.05 $ 0.217  Millions$ 4.115  Millions
Prophase Labs Inc   0.05 $ 3.150  Millions$ 60.428  Millions
Alector Inc   0.05 $ 13.863  Millions$ 267.823  Millions
Seer Inc   0.05 $ 14.377  Millions$ 283.365  Millions
Monte Rosa Therapeutics Inc   0.05 $ 28.727  Millions$ 584.022  Millions
Insight Molecular Diagnostics Inc   0.05 $ 1.670  Millions$ 34.891  Millions
Dar Bioscience Inc   0.05 $ 1.345  Millions$ 28.355  Millions



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.